Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages

Biomaterials

Volumn 34, Issue 2, 2013, Pages 598-605

  Park, Spencer ^a   Kang, Sungkwon ^a   Chen, Xiaoyue ^a   Kim, Esther J ^a   Kim, Jeeyoung ^a   Kim, Nahae ^b   Kim, Juyoung ^b   Jin, Moonsoo M ^a,c  

^a Cornell University   (United States)

^b Kangwon National University   (South Korea)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; ICAM 1; Inflammation; Nanoparticle; Targeted drug delivery

Indexed keywords

AMPHIPHILIC POLYMER NANOPARTICLES; CANCER; CELLULAR COMPONENTS; CERVICAL CANCER CELLS; CROSS-REACTIVITY; DRUG CARRIER; FUNCTIONALIZED; HIGH AFFINITY; ICAM-1; INFLAMMATION; INTEGRINS; PACLITAXEL; SOLID TUMORS; TARGETED DRUG DELIVERY; TUMOR MARKERS; TUMOR SUPPRESSION; TUMOR VASCULATURE; TUMOR-STROMA;

BIOMARKERS; DRUG DELIVERY; MACROPHAGES; NANOPARTICLES; PATHOLOGY;

TUMORS;

ALANINE AMINOTRANSFERASE; ALPHA INTEGRIN; ASPARTATE AMINOTRANSFERASE; CD31 ANTIGEN; CD68 ANTIGEN; DRUG CARRIER; INTERCELLULAR ADHESION MOLECULE 1; NANOPARTICLE; PACLITAXEL; POLYPROPYLENE; UNCLASSIFIED DRUG; URETHANE ACRYLATE NONIONOMER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOENGINEERING; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; CROSS REACTION; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG SELECTIVITY; DRUG TARGETING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; INTERNALIZATION; LIVER INJURY; LIVER TOXICITY; MACROPHAGE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CANCER; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGES; MICE; MICE, SCID; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

MURINAE;

EID: 84868193089     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.004     Document Type: Article

References (45)

1. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
2. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
3. Hambley T.W., Hait W.N. Is anticancer drug development heading in the right direction?. Cancer Res 2009, 69:1259-1262.
4. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999, 1:241-263.
5. Danquah M.K., Zhang X.A., Mahato R.I. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev 2011, 63:623-639.
6. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
7. Kong G., Braun R.D., Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000, 60:4440-4445.
8. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 2006, 12:917-923.
9. Watson K.D., Lai C.Y., Qin S., Kruse D.E., Lin Y.C., Seo J.W., et al. Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res 2012, 72:1485-1493.
10. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
11. Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61:711-716.
12. Turk M.J., Waters D.J., Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 2004, 213:165-172.
13. Chen X., Wong R., Khalidov I., Wang A.Y., Leelawattanachai J., Wang Y., et al. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials 2011, 32:7651-7661.
14. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
15. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
16. Ogawa Y., Hirakawa K., Nakata B., Fujihara T., Sawada T., Kato Y., et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 1998, 4:31-36.
17. Kelly C.P., O'Keane J.C., Orellana J., Schroy P.C., Yang S., LaMont J.T., et al. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. Am J Physiol 1992, 263:G864-G870.
18. Passlick B., Izbicki J.R., Simmel S., Kubuschok B., Karg O., Habekost M., et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994, 30A:376-381.
19. Tomita Y., Nishiyama T., Watanabe H., Fujiwara M., Sato S. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 1990, 46:1001-1006.
20. Koyama S., Ebihara T., Fukao K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 1992, 118:609-614.
21. Shimoyama S., Gansauge F., Gansauge S., Widmaier U., Oohara T., Beger H.G. Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas. Pancreas 1997, 14:181-186.
22. Buitrago D., Keutgen X.M., Crowley M., Filicori F., Aldailami H., Hoda R., et al. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann Surg Oncol 2012, 19:973-980.
23. Schroder C., Witzel I., Muller V., Krenkel S., Wirtz R.M., Janicke F., et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 2011, 137:1193-1201.
24. Roland C.L., Dineen S.P., Toombs J.E., Carbon J.G., Smith C.W., Brekken R.A., et al. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood) 2010, 235:263-270.
25. Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., et al. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 2003, 112:99-111.
26. Jin M., Song G., Carman C.V., Kim Y.S., Astrof N.S., Shimaoka M., et al. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proc Natl Acad Sci U S A 2006, 103:5758-5763.
27. Kang S., Park T., Chen X., Dickens G., Lee B., Lu K., et al. Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery. Biomaterials 2011, 32:3487-3498.
28. Park S., Kang S., Veach A.J., Vedvyas Y., Zarnegar R., Kim J.Y., et al. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials 2010, 31:7766-7775.
29. Wong R., Chen X., Wang Y., Hu X., Jin M.M. Visualizing and quantifying acute inflammation using ICAM-1 specific nanoparticles and MRI quantitative susceptibility mapping. Ann Biomed Eng 2011, 40:1328-1338.
30. Karathanasis E., Chan L., Karumbaiah L., McNeeley K., D'Orsi C.J., Annapragada A.V., et al. Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One 2009, 4:e5843.
31. Sarin H., Kanevsky A.S., Wu H., Sousa A.A., Wilson C.M., Aronova M.A., et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 2009, 7:51.
32. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
33. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
34. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008, 105:9343-9348.
35. Serres S., Soto M.S., Hamilton A., McAteer M.A., Carbonell W.S., Robson M.D., et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA 2012, 109:6674-6679.
36. Dienst A., Grunow A., Unruh M., Rabausch B., Nor J.E., Fries J.W., et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005, 97:733-747.
37. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997.
38. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007, 74:72-84.
39. Yoong K.F., McNab G., Hubscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998, 160:3978-3988.
40. Muro S., Gajewski C., Koval M., Muzykantov V.R. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 2005, 105:650-658.
41. Mizoi T., Ohtani H., Suzuki Y., Shiiba K., Matsuno S., Nagura H. Intercellular adhesion molecule-1 expression by macrophages in human gastrointestinal carcinoma: possible roles as host immune/inflammatory reaction. Pathol Int 1995, 45:565-572.
42. + T cell-mediated tumor rejection in vivo. J Immunol 2005, 174:3416-3420.
43. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534.
44. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
45. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.